Provided by Tiger Trade Technology Pte. Ltd.

BioVie Inc

1.16
+0.03002.65%
Post-market: 1.08-0.0800-6.90%19:53 EST
Volume:55.95K
Turnover:62.94K
Market Cap:8.67M
PE:-0.28
High:1.17
Open:1.09
Low:1.08
Close:1.13
52wk High:20.30
52wk Low:1.06
Shares:7.48M
Float Shares:7.44M
Volume Ratio:0.39
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1489
EPS(LYR):-12.1239
ROE:-80.74%
ROA:-47.20%
PB:0.45
PE(LYR):-0.10

Loading ...

BRIEF-Option Therapeutics Files For IPO Of 2.3 Million Shares Of Common Stock - SEC Filing

Reuters
·
Jan 26

Option Therapeutics Inc Says Thinkequity Is the Underwriter to IPO

THOMSON REUTERS
·
Jan 26

BioVie Inc. unveils new data on bezisterim's potential in Parkinson's and Alzheimer's therapies

Reuters
·
Jan 11

BioVie Completes Enrollment for Phase 2 SUNRISE-PD Trial Testing Bezisterim in Early Parkinson’s Disease

Reuters
·
Jan 08

BioVie Inc - Topline Results From Sunrise-Pd Trial Expected in 1H 2026

THOMSON REUTERS
·
Jan 08

BioVie Completes Enrollment in Phase 2 Sunrise-Pd Trial in Early Parkinson’s Disease

THOMSON REUTERS
·
Jan 08

Halozyme Therapeutics Elects Jim Lang to Board of Directors

Reuters
·
Dec 09, 2025

Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9

GlobeNewswire
·
Nov 19, 2025

BioVie Inc. Files Initial Statement of Beneficial Ownership for Director Kameel D. Farag

Reuters
·
Oct 28, 2025

BioVie Inc. Files Initial Beneficial Ownership Statement for Director Amy Suzon Chappell

Reuters
·
Oct 28, 2025

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

GlobeNewswire
·
Sep 26, 2025

BioVie Inc. Announces Date for Upcoming Virtual Annual Stockholders Meeting

Reuters
·
Sep 26, 2025

BioVie Inc. Reports Net Loss of $17.5 Million for Fiscal Year Ending June 30, 2025; R&D Expenses Drop by $13.8 Million

Reuters
·
Aug 16, 2025

Cuong V Do, President & CEO of BioVie Inc., Reports Acquisition of Common Shares

Reuters
·
Aug 14, 2025

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

GlobeNewswire
·
Aug 14, 2025

BioVie Inc. Announces Closing of $12 Million Public Offering

GlobeNewswire
·
Aug 12, 2025

BRIEF-Biovie Announces Pricing Of $12 Million Public Offering

Reuters
·
Aug 08, 2025

BioVie Inc - Units Sold at $2.00 Each, Pre-Funded Units Less $0.0001

THOMSON REUTERS
·
Aug 08, 2025

BioVie Inc. Announces Pricing of $12 Million Public Offering

GlobeNewswire
·
Aug 08, 2025